Forest desmoteplase
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest is initiating a Phase IIb/III study of its stroke agent desmoteplase "to confirm expanded nine-hour treatment window seen in two Phase II studies," the company says Feb. 7. Current treatment (Activase) has a three-hour window. The Desmoteplase in Acute Ischemic Stroke (DIAS2) parallel-design, dose-ranging study will enroll over 150 patients. Data from the DEDAS study, presented at the International Stroke Conference Feb. 4, showed that the novel plasminogen activator improved clinical outcome after 90 days versus placebo, Forest says, although the trial was not powered to show statistical differences. Desmoteplase is derived from the saliva of vampire bats...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.